Skip to main content

Standing Out In The Crowded Biopharmaceutical Contract Manufacturing Market

By March 14, 2019March 9th, 2022No Comments

Andrew Schafer (moderator), Kevin Olson, (interviewer) and Kate Hammeke (subject expert) from Industry Standard Research share data and insights from our CDMO Quality Benchmarking reports that will help CDMOs to better understand how to move their position in the competitive landscape.

Here we’re showing some data on outsourcing drivers from our biologic API benchmarking study, where we asked 121 people who are outsourcing large molecule drug substance manufacturing, what their primary reason for working with CMOs is. As you can see, two of the options capture the bulk of responses. People use CMOs to augment their internal manufacturers supply – about 45% of our respondents – and the other 40% use CMOs for all their manufacturing needs.

Access the webinar on Bioprocess Online, and check out our recent manufacturing reports to learn about your company’s position in the CDMO market.